Novo Nordisk
About
Novo Nordisk A/S (NYSE: NVO) is a Danish multinational pharmaceutical company and the global leader in diabetes care, commanding approximately one-third of the world's insulin market and pioneering the GLP-1 receptor agonist class with its blockbuster products Ozempic for diabetes and Wegovy for obesity. The company has nearly a century of experience in metabolic disease and has leveraged its deep expertise to become the most valuable company in Europe by market capitalization, as demand for its weight loss and diabetes treatments continues to outstrip manufacturing capacity. As an investment, Novo Nordisk offers exposure to the rapidly expanding obesity therapeutics market through a company with proven commercial execution, massive manufacturing scale, and a pipeline of next-generation treatments including oral GLP-1 formulations.
Pharmaceutical Stocks
Novo Nordisk is a pharmaceutical stock powerhouse and the undisputed global leader in GLP-1 therapies, with Ozempic and Wegovy generating explosive revenue growth that has made it Europe's most valuable company and a must-watch holding for pharmaceutical sector investors.
Weight Loss Stocks
Novo Nordisk is the global leader in GLP-1 weight loss and diabetes treatments with Ozempic and Wegovy, dominating the obesity drug market alongside Eli Lilly.
Key Financials NVO
Price
$49.57
Change (1D)
+1.31%
Change (30D)
-2.57%
Change (60D)
+2.29%
Change (90D)
-16.90%
Change (180D)
-27.74%
Change (1Y)
-39.39%
Change (5Y)
+39.10%
P/E Ratio
2.91
EPS (TTM)
$17.01
52-Week Range
$43.08 — $93.80
50-Day MA
$53.30
Volume
10.14M
Data updated Feb 15 · Source: Twelve Data
